Indian Journal of Public Health

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 66  |  Issue : 5  |  Page : 41--44

Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study


Imtiyaz Ahmed Najar1, Shariq Rashid Masoodi2, Shakeel Ahmed Mir3, Moomin Hussain Bhat4, Rakesh Raman Patyar5, Sazal Patyar6 
1 PhD Scholar, Department of Pharmacology, Lovely Professional University, Jalandhar, Punjab, India
2 Professor, Department of Endocrinology, SKIMS Deemed University, Srinagar, Jammu and Kashmir, India
3 Associate Professor, Department of Clinical Pharmacology, SKIMS Deemed University, Srinagar, Jammu and Kashmir, India
4 Senior Resident, Department of Endocrinology, SKIMS Deemed University; Lecturer, Department of Medicine, Government Medical College, Srinagar, Jammu and Kashmir, India
5 Lecturer, Department of Technical Education and Industrial Training, Punjab, India
6 Professor, Department of Pharmacology, Lovely Professional University, Jalandhar, Punjab, India

Correspondence Address:
Sazal Patyar
Department of Pharmacology, Lovely Professional University, Jalandhar, Punjab
India

Background: Diabetes has a negative impact on patient's quality of life (QoL). Comorbidities and polypharmacy further worsen their QoL. Thus, in addition to glycemic control, assessment of QoL is also gaining importance. Objective: The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add-on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride). Materials and Methods: A prospective research was done on T2DM patients with hypertension, who visited a tertiary care referral institute's endocrine outpatient clinic. For 3 months, empagliflozin, 25 mg once daily, was administered as an add-on treatment with metformin, teneligliptin, and glimepiride. In addition to clinical assessment, an Urdu-translated QoL instrument for Indian diabetes patients was used to conduct QoL study. The QoL outcomes prior to empagliflozin add-on were compared with those obtained at the conclusion of the 3 months of treatment. Results: Empagliflozin as an add-on therapy significantly improved various aspects of QoL like role limitation due to physical health, physical endurance, general health, symptom botherness, financial worries, emotional/mental health, and diet satisfaction (P < 0.001). It also improved glycemic and blood pressure parameters significantly. Conclusion: QoL is an essential measure with respect to patient-centered treatment approach. Empagliflozin, as an add-on medication, improved QoL, glycemic parameters and blood pressure in T2DM patients with hypertension. It can be recommended as an add-on, but more research with a larger sample size is required.


How to cite this article:
Najar IA, Masoodi SR, Mir SA, Bhat MH, Patyar RR, Patyar S. Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.Indian J Public Health 2022;66:41-44


How to cite this URL:
Najar IA, Masoodi SR, Mir SA, Bhat MH, Patyar RR, Patyar S. Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study. Indian J Public Health [serial online] 2022 [cited 2023 Feb 1 ];66:41-44
Available from: https://www.ijph.in/article.asp?issn=0019-557X;year=2022;volume=66;issue=5;spage=41;epage=44;aulast=Najar;type=0